Last reviewed · How we verify
FLUAD® influenza vaccine
At a glance
| Generic name | FLUAD® influenza vaccine |
|---|---|
| Also known as | MF59 adjuvanted vaccine |
| Sponsor | University Health Network, Toronto |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults (PHASE4)
- Simultaneous RZV and aIIV4 Vaccination (PHASE4)
- Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PHASE4)
- Gene Signatures of Influenza Vaccine Responses in Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLUAD® influenza vaccine CI brief — competitive landscape report
- FLUAD® influenza vaccine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI